The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 4, 1998, Pages 503-510

  Niewiadomska, H ^a   Jeziorski, A ^a   Olborski, B ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Ki67; P53; PCNA

Indexed keywords

CYCLINE; CYTOKERATIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032432051     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gotteland M., May E., May-Levin F., Contesso G., Delarue J.C., Mouriesse H.: Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER and ER m RNA contents. Cancer 74: 864-871, 1994.
2. Pujol P., Hilsenbesk S.G., Chamness G.C., Elledge R.M.: Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74: 1601-1606, 1994.
3. Horwitz K.B.: Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat. 26: 119-130, 1993.
4. Noltenius H.: Human Oncology. Pathology and clinical characteristics. Urban-Schwarzenberg, Baltimore, vol.3: 993-995, 1988.
5. Gasparini G., Boracchi P., Verderio P., Bevilaqua P.: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki67 and PCNA antigens detected by immunocytochemistry. Int.J.Cancer 57:822-829, 1994.
6. Gasparini G., Pozza F., Meli S., Reitano M., Santini G., Bevilaqua P.: Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki67 and correlation with flow cytometric S-phase and with some features of tumour aggresiveness. Anticancer Res. 11:2015-2021, 1991.
7. Kreipe H., Heidebrecht H.J., Hansen S., Rohlk W., Radzun H.J., Parweresch R.: A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki67. Am.J.Pathol 142: 3-9, 1993.
8. Sitonen S.M., Isola J.J., Rantala I.S., Helin H.J.: Intratumor variation in cell proliferation in breast carcinoma as determinated by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am.J.ClinPathol. 99:226-231, 1993.
9. Betta P.G., Bottero G., Pavesi M., Pastormerlo M., Bellinger D., Tallarida F.: Cell proliferation in breast carcinoma assessed by a PCNA grading system and its relation to prognostic variables. Surg.Oncol., 2:59-63, 1993.
10. Duffy M.J.: Cellular oncogenes and suppressor genes as prognostics markers in cancer. Clin.Biochem. 26:439-447, 1993.
11. Andersen T.I., Holm R., Nesland J.M., Heimdal K.R., Ottestad L., Borrensen A.L.: Prognostic significance of Tp53 alterations in breast carcinoma. Br.J.Cancer 68:540-548, 1993.
12. Caleffi M., Teague M.W., Jensen R.A., Vnencak Jones C.L., Dupont W.D., Parl F.F.: p53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147-2156, 1994.
13. O'Donoghue J.M., Kerin M.J., Given H.F.: The role of the tumour suppressor gene p53. Eur.J.Surg.Oncol. 20:157-177, 1994.
14. Mansour E.G., Ravdin P.M., Dressier L.: Prognostic factors in early breast carcinoma. Cancer 74:381-400, 1994.
15. Leonardi E., Girlando S., Serio G., Mauri F.A., Perrone G., Scampini S., Palma P.D., Barbareschi M.: PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J.Clin.Pathol. 45:416-419, 1992.
16. Locker A.P., Birrel K., Bell J.A., Nicholson R.I., Elston C.W., Blamey R.W., Ellis I.O.:Ki67 immunoreactivity in breast carcinoma: relationship to prognostic variables and short term survival. Eur.J.Surg.Oncol. 18:224-229, 1992.
17. Bolla M., Chedin M., Colonna M., Marron J., Rostaing-Puissant B., Chambaz E.: Prognostic value of Epidermal Growth Factor Receptor in a series of 303 breast cancers. Eur.J.Cancer 28A:1052-1054, 1992.
18. Gasparini G., Bevilacqua P., Pozza F., Meli S., Boracchi P., Marubini E., Sainsbury J.R.C.: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br.J.Cancer 66: 970-976, 1992.
19. Nixon A.J. Neuberg D., Hayes D.F., Gelman R., Conolly J.L., Schnitt S., Abner A., Recht A., Vicini F., Harris J.R.: Relationship of patient age to pathologic features of the tumour and prognosis for patients with stage I or II breast cancer. J.Clin.Oncol. 12:888-894, 1994.
20. Holmberg L., Lindgren A., Norden T., Adami H.O., Bergstrom R.: Age as a determinant of axillary node involvement in invasive breast cancer. Acta Oncol. 31:533-538, 1992.
21. Mittra I., Mac Rae K.D.: A meta - analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastases represent biology or chronology? Eur.J.Cancer 27:1574-1583, 1991.
22. Yoo K.Y., Tajima K., Miura S., Yoshida M., Murai H., Kuroishi T., Lee Y., Risch H., Dubrov R.: A hospital-based case-control study of breast cancer risk factors by estrogen and progesterone receptor status. Cancer Causes Control 4:39-44, 1993.
23. Spataro V., Price K., Goldhirsch A., Cavalli F., Simoncini E., Castglione M., Rudenstam C.M., Collins J., Lindtner J., Gelber R.D.: Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann.Oncol. 3:733-740.
24. Bianchi S., Paglierani M., Zampi G., Cardona G., Cataliotti L., Bonardi R., Zappa M., Ciatto S.: Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer 72:120-125, 1993.
25. Railo M., Nordling S., Boguslawsky K., Leivonen M., Kyllonen L., Smiten K.: Prognostic value of Ki67 immunolabelling in primary operable breast cancer. Br.J.Cancer 68:579-583, 1993.
26. Aaltomaa S., Lipponen P., Papinaho S., Syrjanen K.: Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J.Cancer Res.Clin.Oncol. 119:288-294, 1993.
27. Campani D., De-Negri F., Fabbri R., Martini L., Giani C., Squartini F., Sarnelli R.: Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int.J.Biol.Markers 6:144-150, 1991.
28. Tahan S.R., Neuberg D.S., Differibach A., Yacoub L.: Prediction of early relapse and shortened survival in patients with breast cancer by Proliferating Cell Nuclear Antigen score. Cancer 71:3552-3559, 1993.
29. Pelosi G., Bresaola E., Rodella S., Manfrin E., Piubello Q., Schavon I., Iannucci A.: Expression of Proliferating Cell Nuclear Antigen, Ki67 antigen, Estrogen Receptot protein and tumour suppressor p53 gene in cytologic samples of breast cancer: An immunohistochemical study with clinical, pathobiological and histologic correlations. Diagn. Cytopath. 11:131-140, 1994.
30. Barnes D.M., Dublin E.A., Fisssher C.J., Levison D.A., Mills R.R.: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum.Pathol. 24:469-476, 1993.
31. Davidoff A.M., Herndon J.E., Glover N.S., Kerns B.J., Pence J.C., Iglehart J.D., Marks J.R.: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259-264, 1991.
32. Elledge R.M., Fuqua S.A., Clark G.M., Pujol P., McGuire W.L.: Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res.Treat. 26:225-235, 1993.
33. Jacquemier J., Moles J.P., Penault-Llorca F., Adelaide J., Torrente M., Viens P., Birnbaum D., Theiilet C.: p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br.J.Cancer 69:846-852, 1994.
34. Domagala W., Harezga B., Szadowska A., Markiewski M., Weber K., Osborn M.: Nuclear p53 protein accumulates prferentially in medullary and high-grade duct but rarely in lobular breast carcinomas. Am.J.Pathol., 142:669-674.
35. Elledge R.M., Fuqua S.A., Clark G.M., Pujol P., Allred D.C.: William L.McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res. Treat. 27:95-102, 1993.
36. Domagala W., Striker G., Szadowska A., Dukowicz A., Harezga B., Osborn M.: p53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases. Eur J.Cancer 30A:1527-1534, 1994.
37. Friedrichs K., Gluba S., Eldtmann H., Jonat W.: Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641-3647, 1993.